CN115068445A - Astaxanthin nanoparticle with light stability and preparation method thereof - Google Patents
Astaxanthin nanoparticle with light stability and preparation method thereof Download PDFInfo
- Publication number
- CN115068445A CN115068445A CN202210798254.7A CN202210798254A CN115068445A CN 115068445 A CN115068445 A CN 115068445A CN 202210798254 A CN202210798254 A CN 202210798254A CN 115068445 A CN115068445 A CN 115068445A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- solution
- hesperidin
- nanoparticle
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 83
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 83
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 77
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 77
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 77
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 43
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 42
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 42
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 42
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 42
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229940025878 hesperidin Drugs 0.000 claims abstract description 42
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 235000017060 Arachis glabrata Nutrition 0.000 claims abstract description 13
- 241001553178 Arachis glabrata Species 0.000 claims abstract description 13
- 235000010777 Arachis hypogaea Nutrition 0.000 claims abstract description 13
- 235000018262 Arachis monticola Nutrition 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 235000020232 peanut Nutrition 0.000 claims abstract description 13
- 102000006395 Globulins Human genes 0.000 claims abstract description 5
- 108010044091 Globulins Proteins 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 238000003756 stirring Methods 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 108010049047 Echinocandins Proteins 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 239000012792 core layer Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 11
- 239000002775 capsule Substances 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- 239000011259 mixed solution Substances 0.000 abstract description 6
- 239000011162 core material Substances 0.000 abstract description 5
- 239000012296 anti-solvent Substances 0.000 abstract description 3
- 108050001186 Chaperonin Cpn60 Proteins 0.000 abstract description 2
- 102000052603 Chaperonins Human genes 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 102000005431 Molecular Chaperones Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 2
- 241000244160 Echinococcus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010002493 Arachin Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 aromatic disaccharide Chemical class 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PSQYTAPXSHCGMF-BQYQJAHWSA-N beta-ionone group Chemical group CC1=C(C(CCC1)(C)C)/C=C/C(C)=O PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001749 carotenones Chemical class 0.000 description 1
- 235000005472 carotenones Nutrition 0.000 description 1
- WNPXRNJEBMRJGV-UHFFFAOYSA-N chembl1399590 Chemical compound COC1=CC=CC(C=2N=C3C=CC=CC3=C(N3C(CCCC3)C)N=2)=C1O WNPXRNJEBMRJGV-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Optics & Photonics (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to an astaxanthin nanoparticle with a light-stable shell-core spherical structure and a preparation method thereof, and the astaxanthin nanoparticle with the light-stable shell-core spherical structure is constructed, wherein the core material of the nanoparticle is astaxanthin, the capsule wall material is prepared by compounding chaperonin and hesperidin, and the particle size is in a nanometer level. Astaxanthin has strong ability of scavenging free radicals, but has poor light stability and is easy to be oxidized. The light stability of the astaxanthin can be improved by the methods of nanoparticle coating and antioxidant modification. The separated peanut globulin is the main capsule material and hesperidin is used mainly in improving the light stability of the particle. The preparation method of the nano-particles comprises the following steps: emulsifying the mixed solution of protein and hesperidin with oil phase containing astaxanthin in proper stabilizer to obtain emulsion, precipitating and solidifying the capsule wall material of the emulsion by using an anti-solvent method, and finally filtering or centrifugally collecting nano particles to obtain the light-stable astaxanthin nano particles.
Description
Technical Field
The invention relates to an astaxanthin nanoparticle with light stability and a preparation method thereof, belonging to the field of micro-nano particles.
Background
Astaxanthin is a ketocarotenoid widely distributed in nature and found in marine organisms such as shrimps, crabs, salmon, algae, etc. Astaxanthin is a fat-soluble carotenoid, has strong antioxidant activity and is known as a super antioxidant. The molecular structure of astaxanthin contains two beta-ionone rings, 11 conjugated double bonds and unsaturated alpha-hydroxy ketone, which have relatively active electronic effect and can provide electrons for free radicals or attract unpaired electrons of the free radicals, so that the astaxanthin can easily react with the free radicals to remove the free radicals, thereby playing the roles of oxidation resistance, ultraviolet resistance, wrinkle resistance and the like. Because of the ability of removing free radicals, astaxanthin is also a potential medicine for treating diseases such as cardiovascular diseases, diabetes, stomach diseases and the like, and can relieve eye fatigue, increase the endurance of muscles and improve the immunity of the human body. The method is widely applied to the industries of medical treatment, beauty treatment, health food and the like. But astaxanthin has poor light stability, is easy to decompose when being exposed to light, can fade and inactivate after being exposed to normal light for several hours, has low bioavailability and limits the application of the astaxanthin, thereby having important significance for improving the stability of the astaxanthin.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: astaxanthin has poor photostability, which results in its limited application. The invention provides an astaxanthin nanoparticle with light stability and a preparation method thereof, wherein after astaxanthin is coated by modified microcapsules, a capsule material shell can effectively isolate a core material from the surrounding environment, and the added hesperidin can react with free radicals in the environment, so that the aim of improving the light stability of the astaxanthin nanoparticle is further fulfilled. In the preparation method, the echinocandin is precipitated by utilizing the property of minimum solubility at isoelectric point, the hesperidin is also precipitated by utilizing an anti-solvent precipitation method to separate out a capsule material, and astaxanthin is wrapped to prepare the nano-particles.
The technical scheme is as follows:
a light-stable astaxanthin nanoparticle is in a shell-core spherical structure, an inner core layer is astaxanthin, and an outer shell layer contains conglycinin and hesperidin; and the average diameter of the nanoparticles is in the range of 200-500 nm.
The preparation method of the astaxanthin nanoparticle with the light stability comprises the following steps:
step 2, uniformly mixing the aqueous solution of the conglycinin and the astaxanthin solution, and dropwise adding the hesperidin aqueous solution under the heating condition;
and 3, dropwise adding the solution obtained in the step 2 into acidic water, uniformly stirring, evaporating to remove the solvent, washing and centrifuging the product, and dissolving the product in the water to obtain the astaxanthin nanoparticle solution.
In the step 1, the aqueous solution of the chaperonin is obtained by dissolving the arachin in a PBS solution and dispersing; the concentration of the concanavalin is 0.01-0.06 g/mL.
In the step 1, the concentration of the astaxanthin solution is 1-4g/L, and the adopted solvent is selected from one of ethanol, chloroform and methanol.
In the step 1, the hesperidin aqueous solution with the concentration of 0.005-0.05 wt% is prepared by ultrasonically dispersing and heating hesperidin in water.
In the step 2, the heating condition is 80-90 ℃, the mass ratio of the echinococcus protein to the hesperidin is 3-15:1, and the mass ratio of the echinococcus protein to the astaxanthin is 30-100: 1.
In step 3, the acidic water is water with pH of 3.5-5.5; the conditions for washing the centrifuge were: and cleaning for 2-5 times at a rotating speed of 3000-5000 r/min.
Advantageous effects
The peanut conglobation protein is a vegetable protein, is a salt-soluble protein, is rich in various amino acids, can supplement skin nutrition, nourish the skin, has a good moisturizing effect on the skin, has film forming property and good emulsifying property, has more favorable sulfydryl on the surface, and can easily form a stable reticular protein film with good strength and viscoelasticity due to the interaction of a large amount of free sulfydryl among molecules when the protein is adsorbed on an interface. The peanut chaperone protein as carrier protein has the advantages of safety, no toxicity, no immunogenicity, biodegradability, good biocompatibility and the like, so that the isoelectric point of the peanut chaperone protein is 3.7-5, and the peanut chaperone protein can be precipitated by changing the pH value of a peanut chaperone protein solution and utilizing the property of minimum solubility at the isoelectric point, so that the micro-particle capsule material can be prepared.
The nano-particles with the core-shell structure take the peanut globulin as a main film-forming material, and have the advantages of safety, no toxicity, no immunogenicity, biodegradability, good biocompatibility and the like, so the hydrophobic active substance astaxanthin is loaded into the nano-particles by utilizing the unique spatial structure of the peanut globulin through an anti-solvent precipitation method, the solubility of insoluble substances can be increased, the nano-particles have a good protection effect on easily-oxidized active substances, and the half-life period of the nano-particles can be obviously delayed.
Hesperidin, also known as hesperidin and hesperidin, is prepared by combining one molecule of hesperetin and one molecule of aromatic disaccharide, is a flavanone, is a natural antioxidant, can be dissolved in dilute alkali, pyridine and hot water with the temperature of more than 70 ℃, and has the effects of reducing cholesterol in a human body, resisting oxidation, preventing mildew, reducing blood pressure, resisting viruses, improving the immunity of the organism and the like. Hesperidin is also a basic raw material for preparing dihydroflavonoids, flavonoids and dihydrochalcone medicines, natural antioxidants and food additives (such as low-energy sweeteners), and has good light resistance and heat resistance.
After the capsule wall material of the astaxanthin nanoparticle is compositely modified by hesperidin, the natural antioxidant performance of the hesperidin can endow the wall material with multiple functions such as light stability and the like, so that the defects of easy fading, inactivation and other storage instability of the astaxanthin are overcome, and the bioavailability of the astaxanthin is improved.
Drawings
Fig. 1 is a polarizing electron microscope image of astaxanthin nanoparticles;
FIG. 2 is a graph showing the particle size distribution of the particles of example 2(A) and comparative example 2 (B);
FIG. 3 is a graph of the ultraviolet absorption wavelength of astaxanthin;
FIG. 4 is a standard curve for astaxanthin detection;
fig. 5 is a graph comparing color change in light stability tests.
Detailed Description
In a typical preparation process of this patent, a method for preparing light-stabilized astaxanthin nanoparticles includes the steps of:
And 2, adding distilled water into the round-bottom flask containing the hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring until the solution is transparent.
And 3, slowly dripping the hesperidin aqueous solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition.
And 4, slowly dropping the solution into acidic water at the speed of 600r/min, uniformly stirring, performing rotary evaporation to remove the organic solvent, cooling to room temperature, adding distilled water again, performing centrifugal cleaning for a plurality of times, and finally adding distilled water and performing ultrasonic mixing to obtain the echinococcin-hesperidin-astaxanthin nanoparticle solution.
In the step 1, the concentration of the concanavalin PBS solution is 0.01-0.06g/mL, and the concentration of the astaxanthin-solvent solution is 1-4 g/L; the solvent preferably comprises one of ethanol, chloroform and methanol; the mode of uniform mixing adopts oscillation, stirring or ultrasonic treatment.
In the step 2, the heating temperature is 80-120 ℃.
In the step 3, the heating temperature is 80-90 ℃. The mass ratio of the echinocandin to the hesperidin is 3-15:1, and the mass ratio of the echinocandin to the astaxanthin is 30-100: 1.
In the step 4, the pH value of the solution is adjusted to 3.7-5, the cooling temperature is 20-30 ℃, and the centrifugal cleaning conditions are as follows: cleaning for 2-5 times at a rotating speed of 3000-5000 r/min.
Example 1
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the solution is magnetically stirred for 2 hours at 600r/min to completely disperse the conglycinin. Preparing an astaxanthin-ethanol solution with the concentration of 1mg/mL, and then stirring and mixing 10mL of the astaxanthin solution and 3mL of the concanavalin solution uniformly.
(2) Adding 200mL of distilled water into a round-bottom flask containing 20mg of hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring at 80 ℃ until the solution is transparent.
(3) Slowly dripping the hesperidin water solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 80 ℃.
(4) Slowly dropping the solution into deionized water (pH3.7) with the volume 5 times of that of the solution at 600r/min, uniformly stirring, performing rotary evaporation to remove the organic solvent, cooling to 25 ℃, adding distilled water again at 3000r/min, performing centrifugal cleaning for 2 times, and finally adding distilled water, and performing ultrasonic mixing to obtain the solution of the echinocandin-hesperidin-astaxanthin nano particles.
Example 2
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the solution is magnetically stirred for 2 hours at 600r/min to completely disperse the conglycinin. Preparing an astaxanthin-acetone solution with the concentration of 3.3mg/mL, and then stirring and uniformly mixing 10mL of the astaxanthin solution and 1mL of the conglycinin solution.
(2) Adding 200mL of distilled water into a round-bottom flask containing 28mg of hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring at 100 ℃ until the solution is transparent.
(3) Slowly dripping the hesperidin water solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 85 ℃.
(4) Slowly dropping the solution into deionized water (pH4) with the volume of 5 times at the speed of 600r/min, stirring uniformly, performing rotary evaporation to remove the organic solvent, cooling to 25 ℃, adding distilled water again at the speed of 5000r/min, performing centrifugal cleaning for 2 times, and finally adding distilled water, performing ultrasonic mixing uniformly to obtain the nano-particle solution of the echinococcin-hesperidin-astaxanthin.
Example 3
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the solution is magnetically stirred for 2 hours at 600r/min to completely disperse the conglycinin. Preparing an astaxanthin-ethanol solution with the concentration of 5mg/mL, and then stirring and uniformly mixing 10mL of the astaxanthin solution and 1mL of the conglycinin solution.
(2) Adding 200mL of distilled water into a round-bottom flask containing 41mg of hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring at 110 ℃ until the solution is transparent.
(3) Slowly dripping the hesperidin water solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 90 ℃.
(4) Slowly dripping the solution into deionized water (pH4.3) with the volume 5 times of the volume of the solution at 600r/min, uniformly stirring, performing rotary evaporation to remove the organic solvent, cooling to 27 ℃, adding distilled water again at 5000r/min, performing centrifugal cleaning for 3 times, and finally adding distilled water, and performing ultrasonic mixing to obtain the solution of the conglycinin-hesperidin-astaxanthin nano particles.
Comparative example 1
The difference from example 1 is that: the capsule wall material of the astaxanthin nano-particles is not added with hesperidin.
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the solution is magnetically stirred for 2 hours at 600r/min to completely disperse the conglycinin. Preparing an astaxanthin-ethanol solution with the concentration of 1mg/mL, and then stirring and uniformly mixing 10mL of the astaxanthin solution and 3mL of the conglycinin solution.
(2) Slowly dropping the solution into deionized water (pH3.7) with the volume 5 times of that of the solution at 600r/min, uniformly stirring, performing rotary evaporation to remove the organic solvent, cooling to 25 ℃, adding distilled water again at 3000r/min, performing centrifugal cleaning for 2 times, and finally adding distilled water and performing ultrasonic mixing to obtain the solution of the peanut globulin-astaxanthin nano particles.
Comparative example 2
The difference from example 1 is that: the pH of the deionized water in step 4 was 8.5.
(1) 0.3g of the conglycinin is dissolved in 10mL of PBS solution, and the solution is magnetically stirred for 2 hours at 600r/min to completely disperse the conglycinin. Preparing an astaxanthin-ethanol solution with the concentration of 1mg/mL, and then stirring and uniformly mixing 10mL of the astaxanthin solution and 3mL of the conglycinin solution.
(2) Adding 200mL of distilled water into a round-bottom flask containing 20mg of hesperidin, carrying out ultrasonic treatment for 5min until the hesperidin is uniformly dispersed, and heating and stirring at 80 ℃ until the solution is transparent.
(3) Slowly dripping the hesperidin water solution into the mixed solution of the conglycinin and the astaxanthin under the heating condition of 80 ℃.
(4) Slowly dropping the solution into deionized water (pH8.5) with the volume 5 times of that of the solution at 600r/min, uniformly stirring, performing rotary evaporation to remove the organic solvent, cooling to 25 ℃, adding distilled water again at 3000r/min, performing centrifugal cleaning for 2 times, and finally adding distilled water, and performing ultrasonic mixing to obtain the solution of the peanut globulin-hesperidin-astaxanthin nanoparticles.
1. Testing the shape, the particle size and the encapsulation efficiency of the nano particles
After the nanoparticles prepared in examples and comparative examples were diluted to a certain concentration with deionized water, the median particle diameter and the particle diameter range of the nanoparticles were measured using a laser particle sizer.
Diluting the prepared nano particles to a certain concentration by using deionized water, performing ultrasonic dispersion for 1min under the power of 100W, sucking and dripping the nano particles onto a glass slide by using a dropper, and observing the morphological characteristics of the nano particles by using an electron microscope after a cover glass is modified. The microphotograph of the nanoparticles of example 1 is shown in fig. 1. From the micrograph, it can be seen that the astaxanthin nanoparticles prepared in example 1 have good dispersibility and exhibit a spherical shape.
The nanoparticles of examples and comparative examples were used to calculate the encapsulation efficiency of astaxanthin by: filtering the nanoparticle reaction stock solution, diluting the solution with anhydrous ethanol to a volume of 500M L, taking 10mL to test the absorption intensity of astaxanthin at 489nm wavelength, calculating the mass M of astaxanthin in the filtrate according to the absorption intensity, and adding astaxanthin to the filtrate according to the total mass M of astaxanthin 0 . The envelope rate δ is calculated as: delta 100 x (M) 0 -M)/M
The results are shown in table 1:
TABLE 1
As can be seen from the results in Table 1, the average particle size of the astaxanthin nanoparticles prepared by the composite wall material of the conglycinin and the hesperidin in the experiment is about 400nm, and the particle size is smaller. The nano particles prepared by the method have good encapsulation efficiency which is over 90 percent. On the other hand, when the particle size distribution of example 1 is shown in the regions A and B of FIG. 2, it can be seen that the particle size distribution obtained in example 1 is narrow (region A), mainly concentrated in the range of 200-500nm, while the particle size distribution obtained in comparative example 2 (region B) is not easily uniform by precipitation due to the pH value of the preparation conditions above the isoelectric point of the conglycinin, resulting in a smaller overall particle size and a wider distribution, which makes it impossible to effectively achieve the formation of coated particles and the coating of astaxanthin.
FIG. 3 shows that the maximum absorption wavelength of astaxanthin in absolute ethanol is about 489nm, and the absorbance curves of astaxanthin standards at different concentrations are shown in FIG. 4, and the linearity is good.
2. Photostability test
Dispersing the nanoparticles prepared in the experiment into deionized water to prepare aqueous dispersion with the concentration of 10ppm, presenting the aqueous dispersion into a transparent bottle, and placing the transparent bottle in an ultraviolet radiation box (sunscreen CPS +, 450W/m) 2 The color change was measured after 30min at 45 ℃ to determine the light stability of the samples.
As can be seen from fig. 2, the astaxanthin nanoparticle dispersions prepared in example 1 and comparative example 1 were light red, and the color of the sample of example 1 did not change significantly after 30min of uv irradiation, while the color of the sample prepared in comparative example 1 faded. It should be noted that the hesperidin added to the nanoparticulate capstock of example 1 acts as an antioxidant, thereby protecting the astaxanthin filler from oxidation and improving its photostability.
Claims (7)
1. A light-stable astaxanthin nanoparticle is characterized by being of a shell-core spherical structure, an inner core layer is astaxanthin, and an outer shell layer contains conarachin and hesperidin; and the average diameter of the nanoparticles is in the range of 200-500 nm.
2. A method of preparing photostable astaxanthin nanoparticles as claimed in claim 1, comprising the steps of:
step 1, respectively obtaining an aqueous solution of the companion peanut globulin, an astaxanthin oil solution and an hesperidin aqueous solution;
step 2, uniformly mixing the aqueous solution of the conglycinin and the astaxanthin solution, and dropwise adding the hesperidin aqueous solution under the heating condition;
and 3, dropwise adding the solution obtained in the step 2 into acidic water, uniformly stirring, evaporating to remove the solvent, cleaning and centrifuging the product, and dispersing the product into the water to obtain the astaxanthin nanoparticle solution.
3. The method of preparing astaxanthin nanoparticles with light stability as claimed in claim 2, wherein the aqueous solution of the conglycinin is obtained by dissolving the conglycinin in PBS and dispersing in the PBS solution in the step 1; the concentration of the concanavalin is 0.01-0.06 g/mL.
4. The method of preparing astaxanthin nanoparticles according to claim 2, wherein the astaxanthin solution is prepared in a concentration of 1-4g/L in step 1 by using a solvent selected from ethanol, chloroform and methanol.
5. The method for preparing astaxanthin nanoparticles with light stability as claimed in claim 2, wherein the hesperidin aqueous solution having a concentration of 0.005-0.05 wt% in step 1 is prepared by dispersing hesperidin in water by ultrasound and heating.
6. The method for preparing astaxanthin nanoparticles with light stability according to claim 2, wherein in the step 2, the heating conditions are 80-90 ℃, the mass ratio of the echinocandin to the hesperidin is 3-15:1, and the mass ratio of the echinocandin to the astaxanthin is 30-100: 1.
7. The method for preparing astaxanthin nanoparticles with light stability as claimed in claim 2, wherein in step 3, the acidic water is deionized water with pH of 3.5-5.5; the conditions for washing the centrifuge were: cleaning for 2-5 times at a rotating speed of 3000-5000 r/min.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210604920 | 2022-05-31 | ||
| CN2022106049209 | 2022-05-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115068445A true CN115068445A (en) | 2022-09-20 |
| CN115068445B CN115068445B (en) | 2023-05-26 |
Family
ID=83257735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210798254.7A Active CN115068445B (en) | 2022-05-31 | 2022-07-08 | Light-stable astaxanthin nano-particles and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068445B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001316601A (en) * | 2000-05-02 | 2001-11-16 | Fuji Chem Ind Co Ltd | Stable emulsion for coloring and method for preparing the same |
| JP2008110926A (en) * | 2006-10-30 | 2008-05-15 | Fujifilm Corp | Water-dispersible nanoparticle |
| CN107307403A (en) * | 2017-07-12 | 2017-11-03 | 日照职业技术学院 | A kind of astaxanthin micro and nano powders preparation |
| WO2019059661A1 (en) * | 2017-09-22 | 2019-03-28 | 나노다이아랩 주식회사 | Method for preparing cosmetic composition having biologically active substance dispersed therein |
| CN113368006A (en) * | 2021-06-10 | 2021-09-10 | 河南工业大学 | Preparation method and application of high-water-dispersion H-type or J-type aggregate astaxanthin/lactalbumin/chitosan nano compound |
-
2022
- 2022-07-08 CN CN202210798254.7A patent/CN115068445B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001316601A (en) * | 2000-05-02 | 2001-11-16 | Fuji Chem Ind Co Ltd | Stable emulsion for coloring and method for preparing the same |
| JP2008110926A (en) * | 2006-10-30 | 2008-05-15 | Fujifilm Corp | Water-dispersible nanoparticle |
| CN107307403A (en) * | 2017-07-12 | 2017-11-03 | 日照职业技术学院 | A kind of astaxanthin micro and nano powders preparation |
| WO2019059661A1 (en) * | 2017-09-22 | 2019-03-28 | 나노다이아랩 주식회사 | Method for preparing cosmetic composition having biologically active substance dispersed therein |
| CN113368006A (en) * | 2021-06-10 | 2021-09-10 | 河南工业大学 | Preparation method and application of high-water-dispersion H-type or J-type aggregate astaxanthin/lactalbumin/chitosan nano compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115068445B (en) | 2023-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Nanostructures of protein-polysaccharide complexes or conjugates for encapsulation of bioactive compounds | |
| Tachaprutinun et al. | Preventing the thermal degradation of astaxanthin through nanoencapsulation | |
| Madrigal-Carballo et al. | Biopolymer coating of soybean lecithin liposomes via layer-by-layer self-assembly as novel delivery system for ellagic acid | |
| Zhang et al. | Preparation, properties and interaction of curcumin loaded zein/HP-β-CD nanoparticles based on electrostatic interactions by antisolvent co-precipitation | |
| Xu et al. | Polymeric micelle-coated mesoporous silica nanoparticle for enhanced fluorescent imaging and pH-responsive drug delivery | |
| CN105902401B (en) | A kind of method preparing H- aggressiveness or J- aggressiveness astaxanthin polymer nanometer disperse systems and application | |
| CN109588721B (en) | Carotenoid-protein particle and preparation method and application thereof | |
| CN112205628A (en) | Composite condensate with double embedding functions and preparation method and application thereof | |
| CN113956500B (en) | Zein composite particles, carrying system, preparation method and application | |
| CN110574931A (en) | microencapsulated low-bitter functional soybean polypeptide and preparation method and application thereof | |
| Ye et al. | Ultrasound-assisted pH-shifting remodels egg-yolk low-density lipoprotein to enable construction of a stable aqueous solution of vitamin D3 | |
| Li et al. | Amphiphilic nano-delivery system based on modified-chitosan and ovalbumin: Delivery and stability in simulated digestion | |
| CN111759822B (en) | Nano-selenium-zein composite nano-particles and preparation method thereof | |
| KR20200132584A (en) | Stabilized astaxanthin nanoparticles and its manufacturing method | |
| CN113368006A (en) | Preparation method and application of high-water-dispersion H-type or J-type aggregate astaxanthin/lactalbumin/chitosan nano compound | |
| Zhao et al. | Research progress of starch as microencapsulated wall material | |
| CN107252132B (en) | Casein-carragheen independently fills the preparation method and applications of capsule of nano | |
| Yuan et al. | Delivery of curcumin by shellac encapsulation: Stability, bioaccessibility, freeze-dried redispersibility, and solubilization | |
| Tan et al. | Layer-by-layer self-assembled liposomes prepared using sodium alginate and chitosan: Insights into vesicle characteristics and physicochemical stability | |
| Du et al. | Preparation, characterization and functional properties of ternary composite nanoparticles for enhanced water solubility and bioaccessibility of lutein | |
| CN113812615A (en) | Water-soluble protein-based astaxanthin product and preparation method thereof | |
| CN115068445A (en) | Astaxanthin nanoparticle with light stability and preparation method thereof | |
| CN107970224A (en) | A kind of preparation method and application of lipid-modified magnetic oxygenated graphene composite material | |
| CN115777914A (en) | Slow release delivery carrier based on nutritional functional components embedded in debranched starch-zein composite particles and preparation method thereof | |
| CN114601170A (en) | New method for dissolving heme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |